Michael R Hayden

This inventor holds 21 USPTO granted patents and 17 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Genetic Therapeutics. Top assignees: The University of British Columbia, Xenon Pharmaceuticals Inc., Wisconsin Alumni Research Foundation. Active years: 1996-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael R Hayden. Retrieved from https://idiyas.com/inventor/michael-r-hayden

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 17)

% Patents Active = 61.9

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 210(Granted Patents)

Company Filing History:

13 out of 965

The University of British Columbia

patents

6 out of 110

Xenon Pharmaceuticals Inc.

patents

4 out of 4,254

Wisconsin Alumni Research Foundation

Aspreva Pharmaceuticals Corp.

patent

6. 1 out of 1

Aspreva Pharmaceuticals S.a.

patent

7. 1 out of 5

Hsc Research and Development Limited

patents

8. 1 out of 1,035

Isis Pharmaceuticals, Inc.

patents

9. 2 out of 834,659

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2020

Loading Chart...

Areas of Expertise:

Huntington Disease

Allele-specific Therapy

Cholesterol Modulation

Gene Therapy

Atherosclerosis

IMPDH Inhibitors

Triglyceride Reduction

Recombinant Viruses

Polynucleotide

Apoptosis Modulators

ABC1 Transporter

Vascular Diseases

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10731160 - Allele-specific therapy for Huntington disease haplotypes (2020-08-04),

2. 10533172 - Allele-specific therapy for huntington disease haplotypes (2020-01-14),

3. 9290751 - LPL variant therapeutics (2016-03-22),

4. 9157120 - Methods and compositions for the treatment of huntington's disease (2015-10-13),

5. 9006198 - Selective reduction of allelic variants (2015-04-14),

6. 8957071 - Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors (2015-02-17),

7. 8715968 - Methods and reagents for modulating cholesterol levels (2014-05-06),

8. 8679750 - Methods and compositions for the treatment of Huntington'S disease (2014-03-25),

9. 8067219 - Polynucleotide encoding an ATP binding cassette transporter 1 (ABC1) polypeptide (2011-11-29),

10. 7816075 - Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents (2010-10-19),

11. 7785886 - Methods and reagents for modulating cholesterol levels (2010-08-31),

12. 7696151 - Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents (2010-04-13),

13. 7166584 - Cholesterol transport gene (2007-01-23),

14. 6987001 - Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents (2006-01-17),

15. 6814962 - Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same (2004-11-09),

Sure, here is the article about inventor Michael R Hayden:

Title: Innovator Spotlight: Michael R Hayden - Pioneering Allele-Specific Therapy for Huntington Disease

Introduction:

Michael R Hayden is a prolific inventor based in Vancouver, Canada, with a remarkable portfolio of 21 patents to his name. His groundbreaking work in the field of developing allele-specific therapies for Huntington disease has earned him global recognition in the medical research community.

Latest Patents:

Among his latest patents is the "Allele-specific therapy for Huntington disease haplotypes." This innovative invention focuses on compositions and methods to inhibit mutant HTT mRNA transcription or CAG-expanded HTT protein expression in cells. By targeting differentiating polymorphisms such as rs72239206 and rs363107, Hayden's oligomer sequences offer promising avenues for personalized treatments.

Career Highlights:

Having worked at renowned institutions like the University of British Columbia and Xenon Pharmaceuticals Inc., Hayden's career exemplifies a steadfast commitment to translational research. His dedication to bridging the gap between laboratory discoveries and clinical applications has been instrumental in advancing the field of genetic therapies.

Collaborations:

Throughout his career, Hayden has collaborated with esteemed colleagues such as Simon N Pimstone and Mark Gray-Keller. Their collective efforts have synergized innovative thinking and expertise, leading to impactful developments in precision medicine for neurodegenerative disorders.

Conclusion:

In conclusion, Michael R Hayden's contributions to the field of genetic therapies, particularly in addressing Huntington disease, underscore his visionary approach to healthcare innovation. With a legacy of patents shaping the future of precision medicine, Hayden continues to inspire the next generation of inventors and researchers worldwide.

Profile summary based on public USPTO records.